INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications
- PMID: 23793693
- PMCID: PMC3664347
- DOI: 10.1136/bmjopen-2012-002313
INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications
Abstract
Introduction: This paper describes a planned process evaluation of the Use of a Multidrug Pill In Reducing Cardiovascular Events (UMPIRE) trial, one of several randomised clinical trials taking place globally to assess the potential of cardiovascular drugs as a fixed-dose combination (polypill) in cardiovascular disease prevention. A fixed-dose combination may be a promising strategy for promoting adherence to medication; alleviating pill burden through simplifying regimens and reducing cost. This process evaluation will complement the UMPIRE trial by using qualitative research methods to inform understanding of the complex interplay of factors that underpin trial outcomes.
Methods: A series of semistructured, in-depth interviews with local health professionals and UMPIRE trial participants in India and the UK will be undertaken. The aim is to understand their views and experiences of the trial context and of day-to-day use of medications more generally. The grounded theory approach will be used to analyse data and help inform the processes of the UMPIRE trial.
Ethics and dissemination: The study has received ethical approval for all sites in the UK and India where trial participant interviews will be undertaken. The process evaluation will help inform and enhance the understanding of the UMPIRE trial results and its applicability to clinical practice as well as shaping policy regarding strategies for improving cardiovascular medication adherence.
Keywords: Cardiovascular Disease; Fixed Dose Combination; Medication Adherence; Polypill; Prevention; Process Evaluation.
References
-
- World Health Organisation Cardiovascular diseases (CVDs). Fact Sheet No 317 2012. http://www.who.int./mediacentre/factsheets/fs317/en/index.html (accessed 1 Nov 2012).
-
- Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458–73 - PubMed
-
- Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227–76 - PubMed
-
- Health TGIfG SPACE collaboration: single pill to avert cardiovascular events. http://www.spacecollaboration.org/ (accessed 28 Aug 2012).
-
- Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2012. http://cpr.sagepub.com/search/results?fulltext=umpire&x=0&y=0&submit=yes... (accessed 1 Nov 2012). - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases